Cardiotoxicity induced by chemotherapy and antibody therapy.
Modern cancer therapy employs a combination of chemotherapy, antibody-based therapy, radiotherapy, and surgery to prolong life and provide cure. However, many of the chemotherapy agents and antibodies, either singly or in combination, can affect the cardiovascular system. Common cardiovascular manifestations of these therapies include heart failure, ischemia, hypotension, hypertension, edema, QT prolongation, bradyarrhythmia, and thromboembolism. The patient's age, underlying cardiovascular status, and genetic background, as well as the route of drug administration and dosage, can all contribute to the development of cardiotoxicity. Strategies to monitor for and to manage these effects are discussed in this review.
Yeh
Edward T H
ET
Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA. etyeh@mdanderson.org
D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*
D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D007155:Immunologic Factors